Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen

US12054529B2 · kind B2 · utility

Assignees

• MEDIZINISCHE HOCHSCHULE HANNOVER · DE
• Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE

Inventors

• Renata Stripecke · Hannover, DE
• Constanze Slabik · Heidelberg, DE
• Reinhard Zeidler · Birkenfeld, DE
• Wolfgang Hammerschmidt · Munich, DE

Key dates

• Filing date: Apr 17, 2019
• Grant date: Aug 6, 2024
• Expiry date: Dec 3, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR includes an extracellular antigen-binding domain, including an antibody or antibody fragment that binds to a protein encoded by a herpes virus, or to a protein complex including the protein (herpes virus antigen), wherein the herpes virus antigen is present on the surface of a human cell that is latently infected with said herpes virus and supports the lytic phase of viral replication. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of the cell in the treatment of a medical disorder associated with human herpesvirus, such as herpes virus-associated cancers, chronic active herpes virus infections or primary herpes virus infections. In preferred embodiments the herpes virus is Epstein-Barr virus (EBV) and a preferred herpes virus antigen target of the CAR is the EBV glycoprotein 350/220 (gp350/gp220).